We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

156 hedge funds and large institutions have $789M invested in Intellia Therapeutics in 2018 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 55 increasing their positions, 29 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

208% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 13

90% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 29

42% more capital invested

Capital invested by funds: $557M → $789M (+$232M)

20% more funds holding

Funds holding: 130 → 156 (+26)

16% more call options, than puts

Call options by funds: $7.78M | Put options by funds: $6.72M

4.65% more ownership

Funds ownership: 62.31% → 66.97% (+4.7%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
156
Holders Change
+26
Holders Change %
+20%
% of All Funds
3.57%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
40
Increased
55
Reduced
29
Closed
13
Calls
$7.78M
Puts
$6.72M
Net Calls
+$1.06M
Net Calls Change
+$6.42M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$28M
2
AIM
ARK Investment Management
Florida
+$22.1M
3
BlackRock
BlackRock
New York
+$20.2M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$8.62M
5
Morgan Stanley
Morgan Stanley
New York
+$7.86M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$29.6M
2
AVAI
Atlas Venture Associates IX
Massachusetts
-$10.7M
3
BBA
Baker Bros. Advisors
New York
-$6.95M
4
O
OrbiMed
New York
-$5.74M
5
Invesco
Invesco
Georgia
-$5.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
GIM
26
Granahan Investment Management
Massachusetts
$3.3M +$247K +10,203 +9%
WM
27
WS Management
Florida
$3.28M +$2.91M +120,000 New
CAI
28
Capital Advisors Inc
Oklahoma
$2.95M -$12.4K -513 -0.5%
PP
29
PDT Partners
New York
$2.91M -$212K -8,745 -8%
First Trust Advisors
30
First Trust Advisors
Illinois
$2.86M +$2.53M +104,505 New
Ameriprise
31
Ameriprise
Minnesota
$2.76M +$2.52M +104,021 New
Citigroup
32
Citigroup
New York
$2.75M +$1.48M +61,046 +155%
CS
33
Candriam SCA
Luxembourg
$2.73M +$477K +19,700 +25%
Man Group
34
Man Group
United Kingdom
$2.69M -$1.05M -43,200 -31%
Canada Life
35
Canada Life
Manitoba, Canada
$2.65M +$58K +2,395 +3%
PIMJS
36
PKO Investment Management Joint-Stock
Poland
$2.52M -$1.38M -56,763 -38%
AG
37
Artal Group
Luxembourg
$2.46M – – –
Goldman Sachs
38
Goldman Sachs
New York
$2.38M +$1.32M +54,326 +166%
Allianz Asset Management
39
Allianz Asset Management
Germany
$2.19M +$1.94M +79,889 New
Creative Planning
40
Creative Planning
Kansas
$2.14M +$713K +29,430 +60%
Wells Fargo
41
Wells Fargo
California
$1.95M -$184K -7,585 -10%
Korea Investment Corp
42
Korea Investment Corp
South Korea
$1.85M +$1.64M +67,700 New
Neuberger Berman Group
43
Neuberger Berman Group
New York
$1.78M -$29.6K -1,220 -2%
TCIM
44
TIAA CREF Investment Management
New York
$1.67M +$581K +23,986 +65%
EWM
45
Elmwood Wealth Management
California
$1.65M +$271K +11,204 +23%
TA
46
Teachers Advisors
New York
$1.62M +$496K +20,481 +53%
AllianceBernstein
47
AllianceBernstein
Tennessee
$1.61M +$858K +35,400 +151%
PIM
48
Platinum Investment Management
Australia
$1.5M – – –
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$1.39M +$620K +25,577 +101%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$1.19M +$425K +17,550 +68%
1
2
3 4 5

NTLA Hedge Fund Activity: Q2 2018 in Review

156 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2018, worth a combined $789M — up 42% from $557M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new NTLA positions and 13 closed out — a net gain of 27 holders — while 55 added to existing stakes and 29 trimmed.

The largest buyer was State Street, adding an estimated $28M. The largest seller was Fidelity Investments, cutting an estimated $29.6M.

  • 156 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2018, up from 130 in Q1 2018.
  • Funds reported $789M of Intellia Therapeutics stock for Q2 2018, up 42% quarter-over-quarter.
  • 40 funds opened new Intellia Therapeutics positions in Q2 2018 and 13 closed out, a net change of +27 holders.
  • The largest Intellia Therapeutics buyer in Q2 2018 was State Street, an estimated $28M added.
  • The largest Intellia Therapeutics seller in Q2 2018 was Fidelity Investments, an estimated $29.6M sold.

Based on aggregated 13F filings for Q2 2018.